Preliminary results of Phase 3, randomized, placebo-controlled clinical trial testing the investigative monoclonal antibody LY-CoV555 in hospitalized COVID-19 patients were published in The New England Journal of Medicine. The antibody did not provide a clinical benefit compared to placebo. The trial, which had been halted to new enrollment in late October following a recommendation by the independent Data and Safety Monitoring Board (DSMB), is part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program. The trial is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
The ACTIV-3 trial
From sports automobiles to spy cameras, energy instruments to wireless energy gadgets-guys love technology. LP2M UIN Maulana Malik Ibrahim Malang is pleased to announce that it will likely be internet hosting the 1st International Convention on Engineering, Know-how, and Social Science (ICONETOS) 2019 from 10 to 12 October 2019 in Malang, East Java, Indonesia. This international degree conference its aim to be more specific in the growth and cutting-edge papers related to Engineering, Sciences and Technology. It is going to be revolutionary when superfast 5G cell networks come to our gadgets, vehicles and digital lives.